Introduction
============

RNA splicing is a fundamental process, which contributes to the structural and functional complexity of proteins and influences their regulatory role and tissue specificity ([@b1-br-0-0-833],[@b2-br-0-0-833]). Splicing enhancers in exons are considered to be responsible for the inclusion of exonic sequences in the gene transcript. There is growing evidence that polymorphisms in high impact exonic splicing enhancers (ESEs) strongly influence the activity of disease-associated genes and modify their association with different pathological conditions ([@b3-br-0-0-833]). Bioinformatic resources are available for evaluating the efficiency of ESEs ([@b4-br-0-0-833]).

It has been previously demonstrated that a major role of intragenic DNA methylation is associated with the regulation of alternative splicing ([@b5-br-0-0-833],[@b6-br-0-0-833]). It should therefore be expected that polymorphisms, which modify a G or a C in a CpG dinucleotide, affect the epigenetic profile in exonic sequences that are most frequently found to be methylated ([@b7-br-0-0-833]). In sites of tentative DNA methylation, particularly when located in ESEs, this would lead to allele-specific methylation differences ([@b8-br-0-0-833]). In view of the recently demonstrated impact of DNA methylation on the splicing process ([@b6-br-0-0-833]), it is also expected that exonic CpG polymorphisms may further affect splicing. The presence of ESEs and their relative potential are predictable by bioinformatic analysis. Recent experimental evidence verified the consistency of the computational results with experimentally observed exon inclusion using a minigene ([@b9-br-0-0-833]). It is also evident that CpG-single nucleotide polymorphisms (SNPs) in prominent ESEs of disease-associated genes are of particular importance ([@b10-br-0-0-833],[@b11-br-0-0-833]). Based on this evidence, various studies have focused on genetic variations (SNPs) at CpGs, which may be responsible for predisposition to various pathological conditions, including type 2 diabetes (T2D) ([@b11-br-0-0-833],[@b12-br-0-0-833]).

T2D is a metabolic disorder characterized by high glucose blood levels associated with insulin resistance and relatively low levels of insulin. Together with obesity, blood hypertension and hyperlipidemia, T2D is one of the most frequent conditions associated with metabolic syndrome, which is currently considered a major cause for cardiovascular disease. Genetic association studies for the identification of SNPs associated with these diseases are performed by genome-wide association study ([@b13-br-0-0-833]). However, the distinct epigenetic/splicing-associated role of these SNPs has not, to the best of our knowledge, been addressed, despite previous evidence that the expression of different splicing isoforms is a major factor for disease association even in the heterozygous state ([@b14-br-0-0-833],[@b15-br-0-0-833]).

In view of the above, a bioinformatic analysis of synonymous SNPs in all T2D-associated genes ([@b11-br-0-0-833]) was performed in the present study to identify prominent CpG-SNPs, which introduce major modifications in the splicing potential of exonic sequences, which may be responsible for T2D. This analysis identified two principle CpG-SNPs, rs5404 in solute carrier family 2, member 2 (SLC2A2), and rs3749166 in calpain (CAPN10), a membrane protease, which is involved in glucose transporter (GLUT)4 translocation ([@b16-br-0-0-833]). rs3749166 (A\>G) is located in exon 11 of the *CAPN10* gene and rs5404 (C\>T) in exon 5 of the SLC2A2 gene. The two CpG-SNPs introduce pronounced changes in the ESE score (splicing potential) of the corresponding exonic sequences in these genes. The association of CAPN10 SNP with T2D in particular, has been addressed in previous studies ([@b17-br-0-0-833]--[@b22-br-0-0-833]).

In the present study, the association of these two epigenetic CpG-SNPs were analyzed, which introduced the greatest changes of the splicing potential in the corresponding genes, with T2D and other metabolic syndrome-associated pathological conditions (arterial hypertension and obesity). In addition, the possibility that this association might be observed only in the heterozygotic state of these SNPs was investigated.

Materials and methods
=====================

### Study population

The investigated population included 99 non-diabetic control participants ([Table IA](#tI-br-0-0-833){ref-type="table"}) and 71 T2D patients ([Table IB](#tI-br-0-0-833){ref-type="table"}). Participants were classified as having T2D based on the American Diabetic Association criteria ([@b23-br-0-0-833]) as follows: i) ≥126 mg/dl fasting plasma glucose concentration; ii) glycosylated plasma hemoglobin (HbA1c) ≥6.5%; iii) insulin use; iv) use of other diabetes medication. All participants provided their medical family history, smoking habits and dietary information, followed by written informed consent. Their names were anonymized prior to study completion. The methods followed in the present study were performed according to the Declaration of Helsinki.

The present study was approved by the Bioethics Committee of Aristotle University Medical School (Thessaloniki, Greece; protocol no. 2629; 19 April 2011), the Scientific Council of Thessaloniki Panagia General Hospital (Thessaloniki, Greece; protocol no. A9825; 9 June 2011) and the Research Committee of Aristotle University, Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heracleitus II (project no. 87113).

### Anthropometric and biochemical analysis

Anthropometric measurements, including weight and height were obtained according to standardized protocols. The epidemiological profile consisted of age, gender, metabolic family history, smoking status, dietary conditions, and accompanying diseases (arterial hypertension and hyperlipidemia). Participants were classified as having an accompanying disease (arterial hypertension and hyperlipidemia) when the use of antihypertensive or antihyperlipidemic medication was reported respectively, independently of their biochemical lipid profile determination. Information regarding the type of medication (tablets and insulin) and potential diabetic complications were recorded for the diabetic patients.

The biochemical analysis included determination of fasting plasma glucose, HbA1c, total serum cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and serum triglycerides. Peripheral blood samples (2 ml) from all 170 participants for molecular genetic analysis were collected in tubes containing EDTA and centrifuged at 4,500 × g for 20 min at room temperature. Buffy coat leukocytes were then isolated and stored at −20°C.

### DNA extraction and genotype analysis

Genomic DNA was extracted from the buffy coat fraction prepared as described above using PureLink Genomic DNA kit (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s instructions. DNA integrity was verified by gel electrophoresis (70 V/cm for 20 min) using 0.8% agarose gel and ethidium bromide staining. DNA purity was determined by the optical density (OD)~260~/OD~280~ nm absorption ratio using an Eppendorf Biophotometer. Genomic sequences containing SNPs (rs3749166 and rs5404) were amplified by DNA polymerase chain reaction (PCR) using Platinum Taq DNA polymerase (Invitrogen; Thermo Fisher Scientific, Inc.). The PCR conditions for rs3749166 amplification were as follows: 94°C for 2 min, 35 cycles of 94°C for 45 sec, 60°C for 45 sec and 72°C for 1.5 min followed by 72°C for 10 min. A forward primer (5′-CAGGTCCCAGAGGGTGGAA-3′) and a reverse primer (5′-CAGGTAGGTGGAGGGCACAA-3′) were used for amplifying a 153-bp fragment containing SNP rs3749166. A 344-bp fragment containing SNP rs5404, was amplified by PCR using a forward primer (5′-TCAGGGAGGGGCTTTCATTC-3′) and a reverse primer (5′-CAGTCAGGGAGGGACGAGA-3′) under the following conditions: 94°C for 2 min, 35 cycles of 94°C for 45 sec, 58°C for 45 sec and 72°C for 1.5 min followed by 72°C for 10 min. Primer design was facilitated by Primer-BLAST (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>), an online primer designing tool ([@b24-br-0-0-833]). Twelve microliters of each PCR product were separated (70 V/cm for 20 min) on a 2% agarose gel and visualized using ethidium bromide staining. In addition, the PCR products were purified using a PureLink PCR Purification kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s instructions. The sequence of the purified PCR products was verified by commercial sequence analysis (VBC-Biotech Service GmbH, Vienna, Austria) using the forward primer for rs3749166 and the reverse primer for rs5404). Nucleotide sequence analysis was performed using the Chromas software (version 2.6.2).

### Personal Genome Project (PGP) data

To validate the results of the analysis, the allele frequencies of the rs5404 and rs3749166 polymorphisms were evaluated using public genome and exome data, available through the PGP repository ([@b25-br-0-0-833]). Cases matching the patient and non-diabetic control profiles of the present study were selected and 40 additional cases (35 non-diabetic controls and 5 T2D patients) were included, containing allele information of the rs3749166 polymorphism. In addition, 71 cases (48 non-diabetic controls and 23 T2D patients) with allele information of the rs5404 polymorphism were evaluated. Among these, 35 non-diabetic controls and 5 T2D patients contained genetic data for the two polymorphisms. Of the 71 PGP individuals, 32.4% were female and the mean age was 58 years (standard deviation, 10.85).

### Statistical analysis

Graphpad online tool (<https://www.graphpad.com>) was used to perform statistical analyses. Student\'s t-test was used to compare groups of continuous variables, and the χ^2^ and Fisher\'s test were used to compare the proportions of genotypes or alleles. A two-tailed P\<0.05 was considered to indicate a statistically significant difference. The difference of the ESE scores between the major S~A~ and minor S~a~ alleles was calculated as the ΔScore = \|S~A~-S~a~\|.

Results
=======

### Clinical data and statistical analysis of epidemiological parameters

Statistical analysis of the data from T2D patients and non-diabetic control subjects ([Table II](#tII-br-0-0-833){ref-type="table"}) demonstrated that among the T2D patients, fasting glucose levels and ΗbΑ1c were significantly higher (P\<0.0001); however, there was no correlation with accompanying diseases, such as arterial hypertension or hyperlipidemia. By contrast, LDL and triglyceride levels were significantly higher among T2D patients (P\<0.0001; P=0.0052) and HDL levels were significantly lower (P\<0.0001). The observed age difference among T2D patients and non-diabetic control subjects was significant (P\<0.0001), potentially because the majority of individuals with T2D are diagnosed at an older age (data not shown). All other parameters, such as smoking status, did not differ among T2D patients and non-diabetic control subjects in the present study.

### Genotype frequencies for rs3749166 and rs5404 SNPs in T2D patients and non-diabetic control subjects

The rs3749166 polymorphism was detected by PCR amplification (data not shown) and sequencing of a 153-bp PCR fragment, which included the SNP ([Fig. 1A](#f1-br-0-0-833){ref-type="fig"}). Similarly, a 344-bp fragment, including the rs5404 SNP was amplified by PCR (data not shown) and analyzed by sequencing ([Fig. 1B](#f1-br-0-0-833){ref-type="fig"}).

The rs3749166 and rs5404 frequencies for the Greek T2D patients and non-diabetic controls are summarized in [Table III](#tIII-br-0-0-833){ref-type="table"}. Statistical analysis of these data revealed that only the heterozygous rs3749166 genotype (AG, partially epigenetic) was associated with T2D, while the epigenetic genotype (GG) appeared to be protective for the disease (P=0.0262; [Table IIIA](#tIII-br-0-0-833){ref-type="table"}). A more significant positive correlation was obtained when the PGP data were incorporated into the study (P=0.0039; [Table IIIA](#tIII-br-0-0-833){ref-type="table"}).

Analysis of the rs5404 polymorphism from the two sets of data revealed that the homozygous TT genotype was not observed, although the CT frequency was significant (21.28% in T2D patients and 34.69% in non-diabetic control subjects) and that the T genotype may be protective for the disease ([Table IIIB](#tIII-br-0-0-833){ref-type="table"}; P=0.0205 and P=0.0258).

Finally, the association of these splicing-affecting genotype combinations with TD2 was analyzed. The results are presented in [Table IIIC](#tIII-br-0-0-833){ref-type="table"} and reveal that only the AG/CC genotype is strongly associated with T2D in all cases examined \[Greek: P=0.004 and odds ratio (OR), 3.11; PGP: P=0.0008 and OR, 2.67\]. Furthermore, the GG/CC and AG/CT genotypes may be protective for the disease. In addition, the T allele was infrequent among individuals who were homozygous for rs3749166 (GG/CT epigenetic genotype).

### Association of the rs3749166/rs5404 genotype combinations with glucose metabolism

Another common characteristic among carriers of the AG/CC genotype (disease-associated) is the presence of high HbA1c levels (≥8.5%) ([Table IV](#tIV-br-0-0-833){ref-type="table"}; P=0.0002, OR, 5.10) although neither of the polymorphisms was found to be independently associated with the T2D criteria (elevated fasting glucose levels and HbA1c).

Discussion
==========

Elucidating the impact of epigenetic synonymous SNPs, particularly those involved in the regulation of alternatively spliced exons, is critical for understanding the pathogenesis of complex diseases. The polymorphisms included in the present study were selected on the basis of their epigenetic character and because they are the only synonymous SNPs strongly modifying the splicing-associated exonic enhancers associated with glucose transport ([@b11-br-0-0-833]). CAPN10 and GLUT2 participate in complementary transporter systems, which might be expected to act in a concerted manner. CAPN10 is a T2D-associated protease, which facilitates insulin-stimulated GLUT4 translocation via its activity on the distal secretory pathway ([@b16-br-0-0-833]). Although the association of rs3749166 with T2D has been the subject of various reviews and meta-analytic studies, it is still questioned if it may influence the development of T2D independently or in combination with other CAPN10 gene polymorphisms ([@b17-br-0-0-833],[@b18-br-0-0-833]). Furthermore, the second SNP investigated in the present study, rs5404 in SLC2A2, has been evaluated in association with T2D ([@b19-br-0-0-833]--[@b22-br-0-0-833]); however, the obtained results were contradictory. In certain studies ([@b20-br-0-0-833],[@b21-br-0-0-833]) a significant risk was observed among homozygotes, which was similar to the present results, while in another study ([@b19-br-0-0-833]) the minor allele was found to be associated with increased disease risk and with reduced postprandial glucose levels. To the best of our knowledge, the present study is the first to provide a comprehensive concurrent analysis of two SNPs (rs3749166 and rs5404) under investigation, which appear to be critical for the splicing of genes involved in complementary glucose transport systems.

Computational analysis has shown that the two polymorphisms interfere with splicing regulation ([@b11-br-0-0-833]). However, according to the data reported by Karambataki *et al* ([@b11-br-0-0-833]) and summarized in [Table V](#tV-br-0-0-833){ref-type="table"} ([@b4-br-0-0-833]), these SNPs modify the binding potential of splicing factors in different ways. rs3749166 (A allele) in CAPN10 strongly modifies the binding site of 3SS_U2 splicing enhancer of alternatively expressed exon 11 and, thus, may lead to the production of more than one splicing product in AG heterozygotes. By contrast, in its heterozygotic state, rs5404 (T allele) in SLC2A2 modifies the response of the ESE elements in this sequence to serine/arginine-rich (SR) proteins, particularly SRp40 and SF2/ASF (IgM-BRCA1) ([@b26-br-0-0-833]). As the two SNPs modify CpG sequences, they also perturb epigenetic regulation for the homozygotic genotypes AA and TT (but not GG and CC, or AG and CT genotypes); however, they do not introduce functionally significant single amino acid modifications (coding synonymous).

The present results, summarized in [Fig. 2](#f2-br-0-0-833){ref-type="fig"}, indicate that the most protective genotype for T2D is the fully epigenetic genotype. In accordance with the above-mentioned analysis, the heterozygous rs3749166 and rs5404 genotypes are also differently associated with T2D. Carriers of the AG/CC genotype (heterozygous for rs3749166) are significantly more frequent among the T2D patients and exhibit particularly high levels of HbA1c, probably indicating resistance to pharmaceutical intervention for T2D. Similar findings regarding the negative effect associated with the synthesis of two different isoforms have been recently reported in association with heterozygous SNPs causing alternative splicing. For example, Tian *et al* ([@b27-br-0-0-833]) reported a number of disorders associated with alternative exon expression and splicing. In addition, Kurzawski *et al* ([@b14-br-0-0-833]) reported on the effect of epigenetic SNP rs5030952 in CAPN10, which exhibits a heterozygotic association with post-transplant diabetes mellitus.

By contrast, the presence of the apparently protective rs5404 SNP (CT genotype in SLC2A2) is potentially associated with the modified response of CT heterozygotes to different stimuli (based on the data from ESE score analysis at least one novel ESE is formed, which significantly responds to SRp40 proteins). This appears to be particularly significant for carriers of the rs3749166 CAPN10 AG genotype (the combined AG/CT genotype is not T2D-associated, and its carriers do not exhibit particularly high levels of HbA1c. The advantage of epigenetic regulation provided by the C allele and, thus, the ESE response may be lost among TT homozygotes. This could be a possible explanation for the absence of TT homozygotes regardless of the relatively high total frequency of the T allele (21.28%, non-Mendelian genetics).

These findings provide the hypothesis that mutations modifying the response to splicing regulatory mechanisms (epigenetic and ESE) may be associated with strong negative functional changes, and exhibit complex, nonlinear disease associations ([@b28-br-0-0-833]). Provided that functionally significant epigenetic SNPs are frequent ([@b11-br-0-0-833]), this type of genetic variation is expected to have a strong impact on disease and evolution.

A major obstacle in investigating complex pathological conditions, such as metabolic syndrome, is the limited understanding of the regulatory factors involved in the expression of interacting components. Recent evidence indicates the key role of alternative RNA expression in developmental changes ([@b29-br-0-0-833]), and the production of coding and non-coding RNA sequences. Another factor is the complex epigenetic modifications, which may also lead to the expression of different RNA isoforms. The current results indicate likely synergies between synonymous splicing-regulatory epigenetic SNPs, which modify the splicing potential of two different glucose transport-associated genes, and reveal that bioinformatic analysis and careful investigation of the SNPs under investigation may become a powerful tool for identifying potentially significant genetic modifications with respect to splicing.

In conclusion, the results presented above indicate for the first time, to the best of our knowledge, the correlation and disease association of two synonymous epigenetic SNPs, which participate in the regulation of the glucose transport system and introduce exclusively splicing-associated modifications. Taken together, these results reveal that T2D is subject to deregulation by complex splicing mechanisms, which may exhibit heterozygous disease association or protection, depending on the splicing-affecting genetic variation. A detailed bioinformatic analysis of the changes introduced by SNPs would facilitate the understanding of the impact of functional changes introduced by genetic variation.

The present study was co-financed by the European Union (the European Social Fund) and Greek national funds through the Operational Program, 'Education and Lifelong Learning' of the NSRF - Research Funding Program: Heracleitus II. Investing in knowledge society through the European Social Fund (project no. 87113).

![(A) Nucleotide sequence of the amplified fragments containing the rs3749166 (A\>G) calpain 10 polymorphism for samples 34, 40, 187, 200, 46 and 117 (rows 1--6, respectively). (B) Nucleotide sequences of the amplified fragments of rs5404 (C\>T) solute carrier family 2 member 2 for the samples 3, 68, 74, 19, 47 and 77 (rows 1--6, respectively). rs3749166 and rs5404 polymorphic sites are indicated using arrows.](br-06-02-0146-g00){#f1-br-0-0-833}

![Frequencies of combined observed and expected genotypes resulting from rs3749166 and rs5404 single nucleotide polymorphism in all analyzed cases. The T2D patient frequencies are presented in parenthesis. The genotypes are presented in order of decreasing epigenetic character. Missing combined genotypes are also included. T2D, type 2 diabetes.](br-06-02-0146-g01){#f2-br-0-0-833}

###### 

Genotypes and epidemiological parameters (age, gender, BMI, metabolic, family history, smoking status, dietary conditions and accompanying diseases) of non-diabetic control subjects (Table A) and T2D patients (Table B).

  A, Non-diabetic control subjects                                                                                                                                                                                                                  
  ---------------------------------- ------- ------------- -------- ------ ------------------ ----------- -------- ------------ ------- -------------- ------------- ------------- ------------- ---- ---------------- ------------ --------- ----- ----------
  1                                      1     65          M          23                      G/G         C/C      110          5.9     106              80            36            95               \+                            \+              
  2                                      3     47          F          25                      A/A         C/C        85         5.3     178            139             46          150                \+                                            HL
  3                                      4     58          F          21                      A/G         C/C        84         5.4     223            182             59          146                                                              
  4                                      6     71          F          22                      A/G         C/T      110          6.4     220            182             63          131                                                              HL
  5                                      7     80          F          28                      A/A         C/C      106          6.0     163            141             42            69                                                             HT
  6                                      9     77          F          26                      A/A         C/C        96         5.6     353            305             51          190                                                              HL
  7                                    10      60          F          29                      A/G         C/T      118          6.2     153            111             40          174           \+                                                 HT/HL
  8                                    12      58          M          34                      A/G         C/C        94         5.6     177            143             33          139                \+                                            HT
  9                                    13      54          M          25                      A/G         C/T      104          5.7     267            219             67          177                                                              
  10                                   14      50          F          35                      A/A         C/C        98         5.6     298            256             53          160                                                              HL
  11                                   16      66          F          24                      G/G         C/C      110          5.9     185            153             60          104                                                              HT/HL
  12                                   19      50          F          35                      G/G         C/T        82         5.6     225            194             31          126                \+                            \+              
  13                                   20      68          F          32                      A/G         C/C        88         5.5     215            184             53          103                                                              HT
  14                                   21      75          M          28                      A/A         C/C        87         5.6     112              92            28            76               \+                                            HT
  15                                   23      50          M          22                      A/G         C/T        87         5.2     239            206             61          106           \+                                                 
  16                                   25      76          F          29                      A/G         C/T        98         5.6     236            186             49          204                                                              HT/HL
  17                                   26      65          F          26                      A/G         C/T      107          5.8     187            152             57          118           \+                                                 HT/HL
  18                                   27      54          F          29                      G/G         C/C      107          5.9     250            218             56          106                \+                                            HL
  19                                   28      57          F          46                      A/G         C/T      115          6.0     239            200             51          143                                              \+              HT/HL
  20                                   29      80          F          24                      A/G         C/C        83         5.3     188            161             63            73                                                             HT/HL
  21                                   30      80          F          27                      A/A         C/C        85         5.4     212            180             58          100                                                              HT/HL
  22                                   31      77          M          31                      A/G         C/C        89         5.6     178            154             38            82                                                             HT
  23                                   32      66          M          26                      A/G         C/T        92         5.6     229            188             50          159                                                              
  24                                   37      54          F          28                      A/A         C/C      110          5.8     230            198             40          124           \+                                                 HT/HL
  25                                   38      69          M          29                      A/A         C/T      101          5.9     202            153             40          209                \+                                            HT/HL
  26                                   39      52          F          35                      A/A         C/T        95         5.6     171            119             40          220                                                              HL
  27                                   40      74          F          23                      G/G         C/C      100          5.7     172            143             69            79                                                             HT/HL
  28                                   43      45          F          38                      A/G         C/T      100          5.7     216            190             38            96                                                             
  29                                   44      56          M          38                      A/A         C/C        78         5.6     179            144             50          128                                                              
  30                                   48      71          F          27                      A/G         C/T      101          5.8     171            122             33          215                                                              HT/HL
  31                                   50      79          M          23                      A/G         C/C        91         5.6     167            134             46          123                                                              HT/HL
  32                                   51      45          F          34                      A/G         C/T        88         5.6     242            199             49          167           \+                                                 HL
  33                                   52      52          F          31                      A/A         C/C        94         5.6     211            162             41          208                                                              HL
  34                                   54      58          M          36                      A/G         C/T      111          5.8     154            113             40          167                                                              HT
  35                                   56      61          F          31                      A/G         C/C      101          6.2     257            216             52          155                                                              
  36                                   58      76          F          28                      A/G         C/C      107          5.8     259            228             73            83                                                             HT
  37                                   59      69          F        31.5                      A/G         C/C      103          5.7     202            172             48          103                                                              HT
  38                                   60      73          F          25                      A/G         C/C        90         5.4     222            190             53          109                                                              HT
  39                                   61      45          F          34                      G/G         C/C        89         5.2     173            144             51            97                                                             
  40                                   63      66          M          30                      A/A         C/T      117          6.4     170            138             41          121                \+                                            HT/HL
  41                                   64      60          F          30                      A/G         C/C        93         5.6     170            131             40          155                                                              HT/HL
  42                                   66      65          F          28                      A/G         C/C        98         5.6     193            150             41          171                                                              
  43                                   67      45          F          17                      G/G         C/T        98         5.0     176            147             53            93                                                             
  44                                   68      63          F          28                      A/G         C/C        90         5.1     214            185             57            92                                                             HL
  45                                   70      50          F          33                      A/G         C/T      105          6.4     217            180             48          137                                              \+              HL
  46                                   71      62          F          28                      A/G         C/C      109          6.0     263            220             62          152                                                              HL
  47                                   75      60          F          29                      G/G         C/C        88         5.6     225            192             48          114                                                              HT
  48                                   76      52          M          25                      G/G         C/C        91         5.5     197            160             54          134                                                              
  49                                   77      50          F          25                      A/A         C/T        99         5.6     210            168             42          168                                                              HL
  50                                   78      58          F          25                      A/G         C/C        88         5.3     249            214             81            93                                                             HL
  51                                   81      70          F          29                      G/G         C/C      117          5.8     212            172             49          150           \+                                                 HL
  52                                   84      55          F          32                      G/G         C/C        95         5.4     218            187             49          103                                                              HT/HL
  53                                   85      53          F          25                      A/A         C/C        91         5.5     223            183             67          132                                                              HT
  54                                   87      65          F          34                      G/G         C/C      106          5.8     240            202             51          139                                                              HT/HL
  55                                   88      49          F          33                      A/G         C/T        98         5.6     213            170             33          185                \+                            \+              HT/HL
  56                                   89      73          F          28                      A/A         C/C      108          6.3     216            188             52            89                                                             
  57                                   90      57          M          32                      A/A         C/C        91         5.5     205            157             30          208                \+                                            HT/HL
  58                                   92      73          F          21                      A/G         C/T      109          5.9     261            215             55          175                                                              HT/HL
  59                                   94      66          F          30                      A/G         C/C      115          6.3     163            132             52          105                                                              HT/HL
  60                                   99      68          M          30                      A/A         C/C        85         5.5     213            163             45          202                                                              HL
  61                                 100       58          F          30                      A/A         C/C        95         5.6     232            203             44          100                                                              
  62                                 101       53          F          27                      A/G         C/T      106          5.7     218            177             64          140                                                              
  63                                 102       59          F          23                      A/G         C/C        95         5.3     169            142             45            89                                                             HT
  64                                 104       78          M          24                      A/A         C/C      100          5.7     211            186             55            70                                                             HT
  65                                 106       64          F          33                      A/G         C/T      108          6.4     208            164             43          177                                                              HT
  66                                 107       47          F          27                      A/A         C/T      105          5.7     239            196             57          155                                                              HL
  67                                 108       43          F          28                      A/A         C/T        89         5.4     159            130             44          103                \+                                            
  68                                 109       71          M          27                      A/G         C/C      101          5.7     171            122             33          215                                                              HT
  69                                 110       57          F          32                      A/G         C/T      104          5.8     220            155             40          286                                                              HL
  70                                 111       60          F          26                      G/G         C/C        99         5.3     167            144             49            65                                                             
  71                                 112       65          F          26                      A/G         C/C        93         5.4     201            165             76          104                                                              HT/HL
  72                                 113       47          F          29                      G/G         C/C      102          5.7     216            180             61          122                                                              
  73                                 114       73          F          24                      A/G         C/C      120          6.2     216            188             52            89                                                             
  74                                 118       46          F          29                      A/A         C/T        88         5.5     148              88            30          267                                                              HT/HL
  75                                 120       58          F          26                      A/G         C/C      104          5.7     263            138             61            61                                                             HL
  76                                 121       56          F          32                      G/G         C/C        87         5.6     187            149             70          120                                                              
  77                                 153       60          F          33                      G/G         C/C        87         5.3     235            200             64          112                \+                            \+              HT/HL
  78                                 155       66          M          26                      A/G         C/C      124          5.7     256            200             45          232                \+                            \+              HT/HL
  79                                 156       50          F          26                      A/G         C/C        93         5.2     256            176             60          337                \+                                            HL
  80                                 158       54          F          24                      A/A         C/T      104          5.7     257            218             62          131                                                              HT
  81                                 159       63          F          25                      A/A         C/C      115          5.8     181            148             64            99                                                             HL
  82                                 161       49          F          22                      A/G         C/T        93         5.3     213            178           100             75               \+                            \+              
  83                                 165       50          F          29                      A/G         C/T        85         5.1     158              84            31          339                                                              HL
  84                                 166       50          M          29                      A/G         C/T      107          5.7     258            215             32          174                \+                                            HL
  85                                 171       52          M          28                      A/A         C/T      101          5.7     213            175             36          151                \+                                            
  86                                 173       51          M          32                      A/G         C/T        78         5.3     191            153             38          151                \+                            \+              
  87                                 174       50          M          28                      A/A         C/T        96         5.0     171            139             38          120                                                              
  88                                 176       80          F          32                      A/G         C/C      121          5.9     158            112             43          183                                                              HT/HL
  89                                 177       71          M          28                      A/G         C/C      105          5.8     220            175             77          144                                                              HT/HL
  90                                 178       56          F          30                      A/G         C/T      108          5.8     182            152             53            93                                                             HT
  91                                 179       67          M          29                      A/G         C/C      105          5.7     179            149             34          112                                                              
  92                                 180       65          F          26                      A/G         C/C        91         5.7     198            168             73            73                                                             HT/HL
  93                                 189       50          F          31                      A/G         C/T        82         5.2     197            168             58            87                                             \+              
  94                                 190       50          M          31                      A/A         C/T        95         5.4     286            228             51          187                                                              HL
  95                                 192       58          F          58                      A/A         C/T        93         5.6     244            210             68          100                                              \+              HT/HL
  96                                 194       52          F          25                      A/G         C/T        85         5.2     219            194             44            81                                             \+              HL
  97                                 195       61          F          27                      A/G         C/C        82         5.6     242            202             69            93                                                             HT/HL
  98                                 196       77          F          39                      A/A         C/C      108          6.2     218            185             71            90                                             \+              HT/HL
  99                                 197       61          F          35                      A/G         C/C        94         5.6     182              49          145           122                                              \+              HT/HL
                                                                                                                                                                                                                                                    
  B, T2D patients                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                    
  S/No.                              n       Age (years)   Gender   BMI    Age of diagnosis   rs3749166   rs5404   FG (mg/dl)   HbA1c   Chol (mg/dl)   LDL (mg/dl)   HDL (mg/dl)   TGL (mg/dl)   FH   Smoking status   Medication   No diet   DC    Diseases
                                                                                                                                                                                                                                                    
  1                                      2     62          M          30     50               A/G         C/C      128          9.4     154            125             39          109                                                        DNA   HT/HL
  2                                      5     60          F          41     35               A/G         C/C      183          8.9     156            128             39          102                                              \+        DNA   HT/HL
  3                                      8     80          F          32     80               A/G         C/C      143            11    177            143             39          134                                 T            \+              HT/HL
  4                                    11      54          F          27     40               A/G         C/C      142          9.5     190            159             55          104                                 T/IN                         
  5                                    15      80          F          23     75               A/A         C/C      128          9.8     135            108             40            98          \+                    IN                     DNA   HT
  6                                    17      71          F          44                      A/A         C/C      144          7.4     150            117             37          129           \+                                 \+        DNA   HT/HL
  7                                    18      65          F          24                      A/G         C/C      206          9.0     204            168             47          136                                 T                            HL
  8                                    22      60          M          28                      A/G         C/C        93         6.1     281            188             39          429                                 T                            HL
  9                                    24      66          F          30                      A/G         C/T      110          7.1     191            164             50            86                                T                      DNA   HT
  10                                   33      57          F          24                      A/A         C/C      177          7.8     219            189             55            97                                T/IN                         HT/HL
  11                                   34      78          F          41     65               G/G         C/T      155          7.5     157            124             40          126           \+   \+               T                            HT
  12                                   35      63          M          36     50               A/A         C/C      254          9.9     252            198             32          1077          \+                    T            \+              HT/HL
  13                                   36      71          F          33     54               A/G         C/C      139          7.8     216            175             54          153                                 T/IN         \+        DNA   HL
  14                                   41      64          M          30     50               A/G         C/T      286          8.8     219            173             31          202           \+                    T/IN         \+        DNA   HT/HL
  15                                   42      80          M          18     60               A/G         C/T      346          10.5    192            162             51          100           \+                    T                      DNA   
  16                                   45      72          F          30     65               A/G         C/C        83         6.4     126              98            29          115                                 T                            
  17                                   46      62          F          31     62               A/A         C/C      168          7.4     223            184             52          148           \+                    Diet                         HT/HL
  18                                   47      73          F          33     60               A/A         C/T      185          8.0     189            156             48          117                                 T                      DNA   HT
  19                                   49      71          M          28     65               A/A         C/C      111          7.6     219            180             45          153                                 T                            HT/HL
  20                                   53      58          F          30     57               A/G         C/C      295          8.7     201            154             43          195                                 Diet                         HL
  21                                   55      67          M          25     55               A/A         C/C      295          10.6    205            162             36          182                \+                                      DNA   HT/HL
  22                                   57      66          F          29                      A/G         C/C      109          7.4     200            153             36          200                                 T                            HL
  23                                   62      79          F          30                      A/G         C/T      151          7.8     169            141             45            99                                T/IN                   DNA   
  24                                   65      59          M          36                      A/A         C/C      130          6.8     125              84            29          178                                 T                            
  25                                   69      63          F          29     40               A/G         C/C        89         7.2     178            133             37          190                                 T                            
  26                                   72      62          F          26                      A/G         C/C      228          8.6     178            133             50          175                                 IN                           HL
  27                                   73      69                     30                      A/A         C/C      171          7.5     166            132             57          114                                 T                            HT/HL
  28                                   74      54          F          24                      A/G         C/C      210          8.6     290            216             32          339           \+                    T                            
  29                                   79      51          M          28                      A/G         C/C      127          7.6     181            127             26          246                                 T/IN                         HT/HL
  30                                   80      70          M          39                      A/A         C/T      134          7.7     152            106             33          200                                 IN           \+        DNA   HT/HL
  31                                   82      68          F          34     40               A/G         C/T      155          8.2     243            186             61          224                                 IN                           HL
  32                                   83      45          F          60     45               A/G         C/C      111          7.8     240            180             27          275                                 Diet         \+              HL
  33                                   86      81          F          28     68               A/G         C/C      132          7.4     171            132             41          156                                 IN                     DNA   HT
  34                                   91      62          F          34     62               A/G         C/T        98         7.2     312            241             41          313           \+                    Diet         \+              HT
  35                                   93      59          F          36     58               A/G         C/C        91         7.2     193            153             40          161                \+               Diet                         HT
  36                                   95      52          F          40     50               A/G         C/T      119          7.0     212            172             53          148                                 T                            HT
  37                                   96      79          F          30     60               G/G         C/C      145          7.6     169            141             49            94          \+                    T                            HT
  38                                   97      45          F          30     37               A/G         C/C      149          7.2     144            102             28          182           \+   \+               T                            HT
  39                                   98      45          F          22     37               A/G         C/C      269          8.8     188            162             60            73          \+   \+               IN           \+              
  40                                 103       62          F          38     52               A/G         C/T      152          7.8     145              80            45          284                                 T            \+        DNA   HT
  41                                 105       67          M          32     57               A/G         C/C      233          8.8     235            182             37          232                \+               T/IN                         
  42                                 115       65          M          19                      A/G         C/C      422          8.9     182            149             41          125           \+                    T                      DNA   
  43                                 116       79          F          32     75               A/G         C/T      151          7.8     151            120             36          124                                 T                      DNA   HT
  44                                 117       74          F          38     67               A/A         C/T      164          7.8     130              93            35          152                                 T/IN                         HT/HL
  45                                 119       45          F          56                      A/G         C/C      167          7.6     191            134             36          250           \+   \+               Diet                         HL
  46                                 151       74          F          31                      A/G         C/C      102          7.2     239            206             62          106           \+                    Diet         \+              HT/HL
  47                                 152       66          F          30     62               A/G         C/C      126          6.8     152            120             34          127           \+   \+               T            \+              HT
  48                                 154       78          M          32     58               A/G         C/C      179          9.1     123              80            33          183           \+                    T/IN         \+        DNA   HT/HL
  49                                 157       73          M          33     58               A/G         C/C      138          7.7     108              85            38            77                                T            \+        DNA   HT
  50                                 160       59          F          48     59               A/G         C/C      148          7.5     190            156             43          130           \+                    T            \+              HT/HL
  51                                 162       68          F          33     45               A/G         C/C      165          8.7     168            122             37          197           \+                    IN                     DNA   HT
  52                                 163       63          M          28     58               A/G         C/C      257          10.3    164            130             38          134                                 T                      DNA   HT/HL
  53                                 164       74          F          30     64               G/G         C/C      124          5.8     181            130             62            93                                Diet                         HT/HL
  54                                 167       72          F          26     46               A/G         C/C      134          7.0     162            137             49            77                                T                            HT/HL
  55                                 169       67          F          28     49               A/G         C/C      125          7.4     167            130             47          141                                 T                      DNA   HT/HL
  56                                 170       73          F          34     48               G/G         C/C      235          10.1    177            134             31          187                                 T/IN                   DNA   
  57                                 172       73          F          35     60               A/G         C/C      192          12.5    153              98            28          248           \+                    T/IN         \+        DNA   HT/HL
  58                                 175       79          F          33     69               A/G         C/C      217          8.8     179              95            30          391                                 T            \+              HT/HL
  59                                 181       78          F          33     62               A/G         C/C      341          8.5     212            160             55          207                                 IN                           
  60                                 182       80          M          29     60               A/G         C/T      130          8.5     171            126             37          192                                 T/IN                   DNA   HT/HL
  61                                 183       80          F          29     75               A/G         C/C      171          7.5     152            117             35          143                                 T                      DNA   HT/HL
  62                                 184       66          F          62     51               A/G         C/T        68         7.8     190            160             47          107                                 IN                           HL
  63                                 185       72          M          47     55               A/G         C/C      269          8.8     243            150             37          429                                 T/IN                   DNA   HT/HL
  64                                 186       78          M          30     75               A/A         C/C      127          7.4     170            145             43            82                                T                            HT
  65                                 187       57          F          26     53               A/G         C/C      240          9.5     256            196             33          271           \+   \+               T            \+              HL
  66                                 188       77          M          30     60               A/A         C/C      154          8.3     229            193             40          141           \+                    T                      DNA   HT
  67                                 191       53          F          32     51               A/G         C/C      114          6.9     216            191             54            74          \+                    T                            HT
  68                                 193       67          M          26                      A/A         C/C      155          7.2     211            181             58            95               \+                            \+              HT/HL
  69                                 198       67          F          30     32               A/G         C/T      167          6.8     228            193             57          122           \+                    T            \+        DNA   HT/HL
  70                                 199       64          F          31     55               A/G         C/C      174          8.2     219            180             47          148           \+                    IN                     DNA   HL
  71                                 200       80          M          29     68               A/G         C/C      163          7.5     155            125             41          113                                 T                      DNA   HT

The + symbol refers to smokers, individuals with a positive family history and those individuals not following a specific diet in the smoking status, FH and no diet columns, respectively. S/No., serial number; n, sample number; BMI, body mass index; F, female; M, male, FG, fasting glucose; HbA1c, glycosylated plasma hemoglobin; Chol, total cholesterol; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; TGL, triglycerides; FH, family history; T, tables; IN, insulin; T/IN, tables and insulin; No diet, no dietary compliance; DC, diabetic complications; DNA, diabetic neuropathy and angiopathy; HT, arterial hypertension; HL, hyperlipidemia; HT/HL, arterial hypertension and hyperlipidemia.

###### 

Statistical analysis of epidemiological parameters of individuals included in [Table I](#tI-br-0-0-833){ref-type="table"}.

  Parameter                                                          Non-diabetic controls^[a](#tfn2-br-0-0-833){ref-type="table-fn"}^ (n=99)   T2D patients^[b](#tfn3-br-0-0-833){ref-type="table-fn"}^ (n=71)   χ^2^     P-value
  ------------------------------------------------------------------ -------------------------------------------------------------------------- ----------------------------------------------------------------- -------- ----------
  Male                                                                 24                                                                         21                                                              0.605    0.4368
  Female                                                               75                                                                         50                                                                       
  Age (years)                                                        60.62±10.11                                                                66.94±9.65                                                                 \<0.0001
  Body mass index (kg/m^2^)                                          28.96±5.34                                                                 32.30±7.98                                                                 0.0013
  Age of T2D diagnosis                                                                                                                          56.37±10.95                                                                
  T2D duration (years)                                                                                                                          11.65±8.33                                                                 
  Fasting glucose (mg/dl)                                            98.31±10.45                                                                170.32±6.63                                                                \<0.0001
  Glycosylated hemoglobin (%)                                        5.65±0.31                                                                  8.13±1.21                                                                  \<0.0001
  Total cholesterol (mg/dl)                                          208.57±38.52                                                               188.96±40.46                                                               0.0016
  Low-density lipoprotein cholesterol (mg/dl)                        147.14±35.00                                                               169.78±36.81                                                               \<0.0001
  High-density lipoprotein cholesterol (mg/dl)                       50.93±13.06                                                                42.14±9.46                                                                 \<0.0001
  Trigycerides (mg/dl)                                               137.18±54.49                                                               179.45±134.09                                                              0.0052
  Family history (positive)                                              6                                                                        25                                                              23.565   \<0.0001
  Smoking status                                                       20                                                                         10                                                              1.065    0.3021
  Not following dietary instructions                                   13                                                                         20                                                              5.977    0.0014
  Diet                                                                                                                                              8                                                                      
  Medication (tablets)                                                                                                                            35                                                                       
  Medication (insulin)                                                                                                                            10                                                                       
  Medication (tablets and insulin)                                                                                                                13                                                                       
  No medication or dietary intervention                                                                                                             5                                                                      
  Diabetic complications (neuropathy, angiopathy)                                                                                                 30                                                                       
  Diabetic complications and disease duration (\>4 years)                                                                                         24                                                                       0.0014
  Diabetic complications and disease duration (≤4 years)                                                                                            1                                                                      
  Accompanying diseases                                                72                                                                         59                                                              2.516    0.1127
  Accompanying diseases (arterial hypertension)                        17                                                                         19                                                              2.278    0.1313
  Accompanying diseases (hyperlipidemia)                               24                                                                         12                                                              1.335    0.2479
  Accompanying diseases (arterial hypertension and hyperlipidemia)     31                                                                         28                                                              1.204    0.2725

Of the 48 PGP non-diabetic controls, 27 are male and 21 are female. The mean age of the 48 PGP non-diabetic controls with one or the two polymorphisms is 59.4 years (SD=10.5).

Of the 23 PGP T2D patients, 21 are male and 2 are female. The mean age of the 23 patients with one or the two polymorphisms is 56.7 years (SD=11.2). T2D, type 2 diabetes; PGP, Personal Genome Project; SD, standard deviation.

###### 

Statistical evaluation of (A) rs3749166 and (B) rs5404 SNP frequencies and genotypes among total and Greek T2D patients and non-diabetic controls. (C) Association of observed rs3749166 and rs5404 genotype combinations with disease among total, and Greek T2D patients and non-diabetic control subjects.

  A, rs3749166 genotypes                                                                                                                                        
  -------------------------------------------- -------------- -------------- ---------------------------------------------------- -------------- -------------- --------------
  Non-diabetic control (total)                 40 (29.85)     71 (52.99)     23 (17.16)                                           11.09          0.0039         
  T2D patients (total)                         15 (19.74)     57 (75.00)     4 (5.26)                                                                           
  Non-diabetic control (Greek)                 29 (29.29)     54 (54.55)     16 (16.16)                                           7.28           0.0262         
  T2D patients (Greek)                         15 (21.13)     52 (73.24)     4 (5.63)                                                                           
                                                                                                                                                                
  B, rs5404 genotypes                                                                                                                                           
                                                                                                                                                                
  Subject                                      TT, n (%)      CT, n (%)      CC, n (%)                                            χ^2^           P-value        
                                                                                                                                                                
  Non-diabetic control (total)                 0 (0)          51 (34.69)     96 (65.31)                                           4.967          0.0258         
  T2D patients (total)                         0 (0)          20 (21.28)     74 (78.72)                                                                         
  Non-diabetic control (Greek)                 0 (0)          39 (39.39)     60 (60.61)                                           5.369          0.0205         
  T2D patients (Greek)                         0 (0)          16 (22.54)     55 (77.46)                                                                         
                                                                                                                                                                
  C, rs3749166 and rs5404 combined genotypes                                                                                                                    
                                                                                                                                                                
  Subject                                      GG/CC, n (%)   GG/CT, n (%)   AG/CC, n (%)                                         AG/CT, n (%)   AA/CC, n (%)   AA/CT, n (%)
                                                                                                                                                                
  Non-diabetic control (total)                 18 (13.43)     5 (3.73)       44 (32.84)                                           27 (20.15)     23 (17.16)     17 (12.69)
  T2D patients (total)                         3 (3.95)       1 (1.32)       43 (56.58)                                           14 (18.42)     12 (15.79)     3 (3.95)
  P-value                                      0.031          0.4211         0.0008^[a](#tfn5-br-0-0-833){ref-type="table-fn"}^   0.7614         0.7973         0.0491
  Non-diabetic control (Greek)                 14 (14.14)     2 (2.02)       29 (29.29)                                           25 (25.25)     17 (17.17)     12 (12.12)
  T2D patients (Greek)                         3 (4.22)       1 (1.40)       40 (56.33)                                           12 (16.90)     12 (16.90)     3 (4.22)
  P-value                                      0.039          1.000          0.004^[b](#tfn6-br-0-0-833){ref-type="table-fn"}^    0.169          0.963          0.100

P-values were evaluated with respect to the disease association of each genotype combination relative to the remaining genotype combinations.

OR=2.67

OR=3.11. T2D, type 2 diabetes; OR, odds ratio.

###### 

AG/CC genotype combination among all individuals and T2D patients, relative to the HbA1c levels (≥8.5%). T2D patients are shown in parenthesis.

                 AG/CC                                                 AA/CC     GG/CC    AG/CT     AA/CT    GG/CT
  -------------- ----------------------------------------------------- --------- -------- --------- -------- -------
  HbA1c ≥8.5%    19 (19)                                               3 (3)     1 (1)    3 (3)         0        0
  HbA1c \<8.5%   50 (21)                                               26 (9)    16 (2)   34 (9)    15 (3)   3 (1)
  Total          69 (40)^[a](#tfn7-br-0-0-833){ref-type="table-fn"}^   29 (12)   17 (3)   37 (12)   15 (3)   3 (1)

P=0.0002, OR=5.10 (P=0.0306, OR=1.30). T2D, type 2 diabetes; HbA1c, glycosylated plasma hemoglobin; OR, odds ratio.

###### 

Evaluation of the ESE modifications introduced by the rs3749166 (A\>G) and rs5404 (C\>T) SNPs using ESE finder \[Cartegni *et al* (4)\].

  Gene     SNP         Exon type      Splice site/SR protein binding       Major allele ESE finder score   Minor allele ESE finder score   ΔScore^[a](#tfn8-br-0-0-833){ref-type="table-fn"}^
  -------- ----------- -------------- ------------------------------------ ------------------------------- ------------------------------- ----------------------------------------------------
  CAPN10   rs3749166   Alternative    Exon 11 splice site (3SS_U2_human)   10.350                          −3.220                          13.570
  SLC2A2   rs5404      Constitutive   SRp40                                3.793                           6.324                           2.531
                                      SF2/ASF (IgM-BRCA1)                  2.337                           3.769                           1.402
                                      SF2/ASF                              3.162                           3.778                           0.616

ΔScore: Difference of the ESE scores between the major and minor allele. Lower splicing score limit according to ESE finder: 3SS_U2_human=6.632; SRp40=2.670; SF2/ASF(IgM-BRCA1)=1.867; SF2/ASF=1.956. ESE, exonic splicing enhancers; SNP, single nucleotide polymorphism; CAPN10, calpain 10; SLC2A2, solute carrier family 2, member 2.
